SELUTION SLR™ 014 In-stent Restenosis

Clinical Inclusion Criteria:

1. Subject age is ≥ 18 years or minimum legal age as required by local regulations.

2. Female subjects of childbearing potential have a negative pregnancy test ≤ 7 daysbefore the procedure.

3. Subject presents with chronic coronary syndrome (CCS) (manifest as documented anginaor positive functional testing), unstable angina or stabilized non-ST-elevationmyocardial infarction (NSTEMI) (biomarkers stabilized or down trending) with anindication for percutaneous coronary intervention (PCI) and planned intervention.

4. Subject is eligible for dual antiplatelet therapy (DAPT) treatment with aspirin pluseither Clopidogrel, Prasugrel, or Ticagrelor. Note: Subjects who require continuedoral anticoagulant therapy my omit aspirin at discretion of investigator.

5. Life expectancy >1 year in opinion of investigator.

6. Subject is willing and able to provide informed consent and comply with studyprocedures and required follow-up evaluations.

Angiographic Inclusion Criteria

1. Target lesion is within a native coronary artery or major branch.

2. Target lesion is within a previously placed BMS or DES and does not extend furtherthan 5 mm beyond either the proximal or distal edge of the stent.

3. Up to two (2) non-target lesions in non-target vessels may be treated, butsuccessful PCI of the non-target lesions must be completed before treatment of thetarget lesion. Successful treatment is defined as no greater than 30% residualstenosis by visual estimate, no dissection greater than National Heart, Lung, BloodInstitute (NHLBI) type C, and Thrombolysis in Myocardial Infarction (TIMI) gradeflow in the non-target lesion > 2.

4. Target lesion is ≤ 26 mm in length.

5. Target lesion has diameter stenosis of > 50% and ≤ 99% by visual estimate.

6. Reference vessel diameter (RVD) is ≥ 2.00 mm and ≤ 4.50 mm.

7. Target lesion must be successfully pre-dilated/pre-treated. Note: Successfulpre-dilation/pre-treatment is defined as dilation or pre-treatment that achievesstent expansion of approximately 80% of the distal RVD (at the discretion of theinvestigator) based on intravascular ultrasound (IVUS)/optical coherence tomography (OCT) and no greater than 30% residual stenosis by visual estimate and no dissectiongreater than NHLBI type C. TIMI grade flow in the target lesion must be > 2. Note:Atherectomy and cutting balloon are permitted for pre-treatment.

Clinical Exclusion Criteria:

1. Known hypersensitivity or allergy to Sirolimus or other pharmacologic agentsrequired for the procedure.

2. ST-elevation myocardial infarction (STEMI) within 30 days.

3. Planned treatment of additional lesions in the target vessel, or more than two (2)non-target lesions within non-target vessels, during the index procedure.

4. Target lesion is located within a bifurcation with planned treatment of side branchvessel.

5. Target lesion is the 3rd or greater stent failure (i.e., more than two [2] layers ofstent are present at any segment of the target lesion).

6. Target vessel had any previous vascular brachytherapy treatment or is planned toundergo brachytherapy at index procedure.

7. Previous PCI of the target vessel within 30 days.

8. Planned PCI of a non-target vessel, or a non-target lesion in the target vessel,within 30 days of randomization.

9. Subject has chronic renal insufficiency (dialysis dependent, or glomerularfiltration rate [GFR] ≤ 30 ml/min/1.73 m² within 30 days of index procedure) or hasundergone renal transplantation.

10. Subject has acute renal insufficiency confirmed by 50% increase of serum creatininewithin 48 hours before procedure and/or decrease in urine output.

11. History of active peptic ulcer or gastrointestinal bleeding within prior 6 months orother inability to comply with recommended duration of DAPT.

12. Subject is pregnant, breast-feeding, or a woman of childbearing potential who is notusing appropriate contraceptives to avoid becoming pregnant.

13. Documented left ventricular ejection fraction (LVEF) < 25%.

14. Currently participating in another investigational drug or device study that has notcompleted primary endpoint follow-up.

Angiographic Exclusion Criteria

1. Target lesion is a total occlusion or has evidence of thrombus.

2. Target lesion involves an unprotected left main.

3. Target lesion has > 30% residual stenosis by visual estimate or dissection greaterthan NHLBI type C after pre-dilation/pre-treatment.